LONDON, August 26, 2016 /PRNewswire/ --

Analysis and Forecasts for Jet Injector Technologies and Competing Technologies Including Novel Needle Technology, Inhaler Technology and Microneedle Technology With an Assessment of Leading Companies Including Antares, Zogenix and 3M

What can be expected from the Needle-Free Delivery Technologies Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects.
 
Our 183-page report provides 105 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national Needle-Free Delivery Technology markets. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.

See revenue forecasts for the leading regional and national markets
How will leading national and regional markets perform to 2026? Our study forecasts revenues in national markets, including:
• US
• EU5 (Germany, France, UK, Italy and Spain)
• Japan
• China
• India
• Rest of the World

Leading companies and potential for market growth
Visiongain forecasts overall revenue for the Needle-Free Delivery Technologies Market will reach $2,093.9m in 2020. We predict high revenue growth over the forecast period, which will driven by the strong demand for improved vaccine and drug delivery methods.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Our work analyses the key companies in the market. See visiongain's analysis of six leading companies, including:
• 3M
• Antares Pharma
• Beckton Dickinson and Company (BD)
• Bioject Medical Technologies
• PharmaJet
• Zogenix

A company profile gives you the following information where available:
• Discussion of a company's activities and outlook including regional and national revenue shares
• Historic revenue, analysis and discussion of company performance
• Analysis of major products/services currently available on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the needle-free drug delivery industry?
Our new report discusses issues and events affecting the needle-free delivery technology market. You will find discussions, including qualitative analyses:
• Highly fragmented and competitive market with significant variations in different geographic regions
• Changing political and regulatory landscape changing the prospects of future products and reimbursement opportunities
• Future opportunities for needle-free delivery technologies

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Needle-Free Delivery Technology Market Forecast 2016-2026: Analysis and Forecasts for Jet Injector Technologies and Competing Technologies including Novel Needle Technology, Inhaler Technology and Microneedle Technology with an Assessment of Leading Companies including Antares, Zogenix and 3M report helps you
In summary, our 183-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the Needle-Free Delivery Technology Market - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2026 for two major submarkets - jet injectors and competing technologies (novel needle technology, inhaler technology and transdermal patch technology)
• Revenue forecasts to 2026 for two major regional markets - EU5 and Rest of the World
• Revenue forecasts to 2026 for the leading national markets - US, Germany, France, UK, Italy, Spain, Japan, China, India and Rest of the World
• Assessment of leading companies - analysis of services, business operations, products, pipelines, revenue (where available) and recent mergers & acquisition activity
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the needle-free drug delivery market and leading companies. You will find data, trends and predictions. Please order our report now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1716/Needle-Free-Delivery-Technology-Market-Forecast-2016-2026

Companies Mentioned in the Report 

3M

Actavis

Activa Brand Products

AcuShot

Adamis

Aktiv-Dry

Alkermes

Alza

Anesiva

Antares Pharma

Aradigm

Astellas Pharma

AstraZeneca

BD

BeadTek

Berlex Labs

Bespak

bioCSL

Bioject Medical Technologies

Biomedics

Boehringer Ingelheim

Bristol-Myers Squibb and Somerset Pharmaceuticals

Cambridge Consultants

CareFusion Corporation

CEA-LETI

Corium International

CosMed

Crossject

CureVac

D'Antonio Consultants International

Debiotech

Durect

Echo Therapeutics

Elcam Medical

Eli Lilly & Co

Endo International

Ethical Holdings/Schering

Eurojet Medical

Ferndale

Georgia Institute of Technology

Giant Eagle

GlaxoSmithKline

Glide Pharmaceutical Technologies

Hangzhou Hema Medical Equipment

Haselmeir GmbH

Health-Mor Personal Care

Hirtenberger

Ichor

iHealthNet

Immunomic Therapeutics

ImmusanT

Injex Pharma

Inovio Pharmaceuticals

Invion

Janssen Pharmaceuticals

Key Pharmaceuticals

Kroger

LEO Pharma

LTS Lohmann Therapie-Systeme

MannKind

Mecaplast

Meda Pharmaceuticals

Medac Pharma

Medical International Technologies

Medi-Ject

MedImmune

Merck

Merck Serono

Micron Biomedical

Mylan

nanoBioSciences

NanoPass

Napp Pharmaceuticals

National Medical Products

Nektar Therapeutics

Nemaura

Nicobrand Limited

Novartis

Novo Nordisk

Novogyne Pharmaceuticals

NuPathe

Nycomed

Ortho-McNeil

Owen MumFord Inc

Par Pharmaceutical

Parke-Davis

Penjet Corporation

Pernix

Pfizer

PharmaJet

PKA SoftTouch Corp

Procter & Gamble

ProStrakan

Purdue Pharma

Radius Health

Rhenovia Pharma

Rite Aid

Roche

Sandoz

Sanofi

Searle Pharmaceuticals

Shire

SHL Group AB

Shwarz-Pharma

Société Nationale des Poudres et Explosifs

STADA Arzneimittel AG

Stat Medical Devices

Takeda

Teva

The Medical House

TheraJect

TheraTech

Transdermal Specialties

Trimeris

Trinity-Chiesi

UCB Pharma

University of California-San Francisco

Vaxxas

Vetter Pharma

Vyteris

Watson

West Pharmaceuticals

Westmount Pharmacy

Ypsomed AG

Zogenix

Zosano

Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

SOURCE Visiongain Ltd